Investigational new drug (IND) - Applications and Submissions
|
Securing clearance for an Investigational New Drug (IND) from the FDA represents the crucial first step towards initiating clinical trials within the United States. Attaining this milestone demands meticulous preparation and a strategic approach during the Pre-IND Meeting. FDA approval of the IND application is imperative before shipping the drugs and initiating the clinical trials.
FDAMap helps in preparing and submitting the error-free IND submission to the FDA to ensure you get the IND approval timely and start your clinical trials. Our FDA IND consultants help at all stages of the IND application or submission. FDAMap as a leading FDA regulatory consulting firm can be of great help in tedious IND submissions to ensure compliance with FDA regulations and guidelines throughout the submission process. Additionally, we maintain open communication with the FDA during the review process so that any questions or concerns that may arise can be addressed effectively. For inquiries on FDA regulatory consulting, and any FDA regulated industry services, please contact Prashant Kumar at 410-501-5777 or write to [email protected] How to Submit an IND Application with the US FDA The IND (Investigational New Drug) filing requirements with the FDA (U.S. Food and Drug Administration) are extensive and complex. Here's a general overview of what is typically required: 1. Cover Letter: A cover letter introducing the submission and providing basic information about the sponsor, the investigational product, and the purpose of the submission. 2. Form FDA 1571: This form serves as the cover sheet for the submission and includes basic information about the investigational product, the sponsor, and the application type. 3. Form FDA 1572: This form is the Statement of Investigator, which is required to be completed by each investigator who will be conducting the clinical trials. It provides assurance that the investigator will comply with FDA regulations. 4. Investigator's Brochure: This document provides a comprehensive overview of the investigational product, including its pharmacological and toxicological properties, as well as information from preclinical studies. 5. Protocol: A detailed protocol outlining the objectives, design, methodology, monitoring, and statistical considerations of the clinical trials. 6. Chemistry, Manufacturing, and Controls (CMC) Information: Detailed information about the composition, manufacturing process, and quality control of the investigational product. 7. Preclinical Data: Data from animal studies that demonstrate the safety and potential efficacy of the investigational product. 8. Clinical Data: Any available preliminary clinical data from previous studies conducted with the investigational product. 9. Clinical Trial Information: Detailed information about the proposed clinical trials, including the study design, inclusion/exclusion criteria, endpoints, and monitoring procedures. 10. Investigational New Drug Application (IND) Fee: Payment of the required fee for IND submission. 11. Additional Information: Any additional information requested by the FDA or deemed necessary for the evaluation of the investigational product. Submitting an IND (Investigational New Drug) application to the US FDA (Food and Drug Administration) involves a structured process. Here's a general overview of the steps involved: 1. Preparation: Before submitting the IND application, ensure that all necessary data, documents, and forms are compiled and organized according to FDA regulations and guidelines. This includes the investigational drug information, preclinical and clinical data, study protocols, and other required documentation. 2. Electronic Submission Gateway (ESG): Most submissions to the FDA are now required to be made electronically through the Electronic Submission Gateway (ESG). This gateway facilitates the secure submission of electronic regulatory documents to the FDA. 3. Obtain Regulatory Information: Review the FDA's regulations, guidance documents, and forms related to IND submissions to ensure compliance with requirements. The FDA's website provides detailed information and resources for IND submissions. 4. Complete Application Forms: You need to fill out the necessary forms for the IND application, including Form FDA 1571 (Investigational New Drug Application), Form FDA 1572 (Statement of Investigator), and any other applicable forms such as Form FDA 3674 (Certification of Compliance with Requirements of ClinicalTrials.gov Data Bank). 5. Compile Supporting Documents: Gather all supporting documents required for the IND application, such as the Investigator's Brochure, preclinical study reports, clinical trial protocols, chemistry, manufacturing, and controls (CMC) information, and any additional data or information requested by the FDA. 6. Submit the Application: Once all required documents are prepared and compiled, you can submit the IND application electronically through the FDA's Electronic Submission Gateway (ESG). You need to carefully follow the instructions provided by the FDA for the submission process, including any specific formatting requirements or technical specifications. 7. Track Application Status: After submission, you can track the status of the IND application through the FDA's electronic submission system. The FDA will review the application and may request additional information or clarification during the review process. 8. FDA Review and Response: The FDA will review the IND application submitted by you to assess the safety and scientific validity of the proposed clinical trials. The FDA may issue a "Notice of Allowability" to proceed with the clinical trials or may request modifications or additional information before it allows you to proceed with your clinical trials. 9. Initiate Clinical Trials: Upon receiving authorization from the FDA, you can initiate the planned clinical trials in accordance with the approved protocols and regulatory requirements. Fill up the inquiry form or Click here to schedule a FREE consultation with our lead FDA consultant Dr. Mukesh Kumar. |
Inquiry Form:
|
